Patent · US Active

DAC HYP compositions

US9815903B2 · kind B2 · utility

5Cited by
2References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 4, 2017
Grant dateNov 14, 2017
Priority date—
Expiry dateMay 4, 2037

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.